{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:58:42Z","timestamp":1740149922729,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 82723"],"award-info":[{"award-number":["CA 82723"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12029-021-00720-z","type":"journal-article","created":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T04:27:19Z","timestamp":1633494439000},"page":"1340-1349","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Relationships Between Indices of Tumor Aggressiveness in Hepatocellular Carcinoma"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6111-5077","authenticated-orcid":false,"given":"Brian I.","family":"Carr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Donghia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seai","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"issue":"2","key":"720_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/lt.25345","volume":"25","author":"CB Sherman","year":"2019","unstructured":"Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. Distinguishing tumor from bland portal vein thrombus in liver transplant candidates with hepatocellular carcinoma: the A-VENA criteria. Liver Transpl. 2019;25(2):207\u201316.","journal-title":"Liver Transpl"},{"key":"720_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/00004836-199203000-00021","volume":"14","author":"CR Taylor","year":"1992","unstructured":"Taylor CR. Computed tomography in the evaluation of the portal venous system. J Clin Gastroenterol. 1992;14:167\u201372.","journal-title":"J Clin Gastroenterol"},{"key":"720_CR3","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/s00330-008-0931-z","volume":"18","author":"S Rossi","year":"2008","unstructured":"Rossi S, Ghittoni G, Ravetta V, et al. Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma. Eur Radiol. 2008;18:1749\u201356.","journal-title":"Eur Radiol"},{"key":"720_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2214\/ajr.168.3.9057522","volume":"168","author":"ME Tublin","year":"1997","unstructured":"Tublin ME, Dodd GD 3rd. Baron RL Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol. 1997;168:719\u201323.","journal-title":"AJR Am J Roentgenol"},{"key":"720_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4172\/2329-6771.1000169","volume":"5","author":"BI Carr","year":"2016","unstructured":"Carr BI, Guerra V, Giannini EG, et al. A liver index and its relationship to indices of HCC aggressiveness. J Intergr Oncol. 2016;5:178. https:\/\/doi.org\/10.4172\/2329-6771.1000169. (PMID: 28580457).","journal-title":"J Intergr Oncol"},{"key":"720_CR6","doi-asserted-by":"publisher","unstructured":"Carr BI, Guerra V, Donghia R et al. Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. Internat J Biol Markers 2021; Feb. https:\/\/doi.org\/10.1177\/1724600821996372","DOI":"10.1177\/1724600821996372"},{"key":"720_CR7","doi-asserted-by":"publisher","first-page":"3120185","DOI":"10.1155\/2018\/3120185","volume":"13","author":"H Akkiz","year":"2018","unstructured":"Akkiz H, Carr BI, Kuran S, et al. Macroscopic portal vein thrombosis in HCC patients. Canad J Gastroenterol Hepatol. 2018;13:3120185. https:\/\/doi.org\/10.1155\/2018\/3120185.","journal-title":"Canad J Gastroenterol Hepatol"},{"issue":"4","key":"720_CR8","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s12029-020-00530-9","volume":"51","author":"BI Carr","year":"2020","unstructured":"Carr BI, Guerra V, Donghia R, Yilmaz SJ. Trends in tumor indices in relation to increased hepatocellular carcinoma size: evidence for tumor evolution as a function of growth. Gastrointest Cancer. 2020;51(4):1215\u20139. https:\/\/doi.org\/10.1007\/s12029-020-00530-9. (Epub 2020 Oct 2).","journal-title":"Gastrointest Cancer"},{"key":"720_CR9","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3748\/wjg.v24.i15.1641","volume":"24","author":"Y Ventura","year":"2018","unstructured":"Ventura Y, Carr BI, Kori I, Guerra V, Shibolet O. Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization. World J Gastroenterol. 2018;24:1641\u20139.","journal-title":"World J Gastroenterol"},{"key":"720_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/j.seminoncol.2014.03.001","volume":"41","author":"P Pancoska","year":"2014","unstructured":"Pancoska P, Carr BI. Macro- and micro-environmental factors in clinical hepatocellular cancer. Semin Oncol. 2014;41:185\u201394.","journal-title":"Semin Oncol"},{"key":"720_CR11","doi-asserted-by":"publisher","unstructured":"Carr BI, Guerra V, Giannini EG et al. Italian Liver Cancer Group. Significance of platelet and AFP levels and liver function parameters for HCC size and survival. Int J Biol Markers. 2014 Sep 30;29(3):e215\u201323. https:\/\/doi.org\/10.5301\/jbm.5000064 (PMID: 24526315).","DOI":"10.5301\/jbm.5000064"},{"issue":"3","key":"720_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1053\/j.seminoncol.2014.04.001","volume":"41","author":"BI Carr","year":"2014","unstructured":"Carr BI, Lin CY. Lu SN Platelet-related phenotypic patterns in hepatocellular carcinoma patients. Semin Oncol. 2014;41(3):415\u201321. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.04.001. (Epub 2014 Apr 23 PMID: 25023358).","journal-title":"Semin Oncol"},{"issue":"2","key":"720_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000484564","volume":"94","author":"H Akkiz","year":"2018","unstructured":"Akkiz H, Carr BI, Yal\u00e7\u0131n KK, et al. Characteristics of hepatocellular carcinoma aggressiveness factors in turkish patients. Oncology. 2018;94(2):116\u201324.","journal-title":"Oncology"},{"key":"720_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4172\/2329-6771.1000178","volume":"5","author":"BI Carr","year":"2016","unstructured":"Carr BI, Guerra V, Giannini EG, et al. A liver index and its relationship to indices of HCC aggressiveness. J Integr Oncol. 2016;5:178. https:\/\/doi.org\/10.4172\/2329-6771.1000178. (Epub 2016 Sep 5 PMID: 28580457).","journal-title":"J Integr Oncol"},{"key":"720_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000444394","volume":"90","author":"BI Carr","year":"2016","unstructured":"Carr BI, Guerra V. A hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels. Oncology. 2016;90:215\u201320.","journal-title":"Oncology"},{"key":"720_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4172\/2329-6771.1000172","volume":"5","author":"BI Carr","year":"2016","unstructured":"Carr BI, Guerra V, Giannini EG, Farinati F. An HCC Aggressiveness Index and blood GTP, bilirubin and platelet levels. Integrative Oncology. 2016;5:172. https:\/\/doi.org\/10.4172\/2329-6771.1000172.","journal-title":"Integrative Oncology"},{"key":"720_CR17","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E","volume":"56","author":"K Okuda","year":"1985","unstructured":"Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer. 1985;56:918\u201328.","journal-title":"Cancer"},{"key":"720_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4103\/0366-6999.150095","volume":"128","author":"JJ Zhao","year":"2015","unstructured":"Zhao JJ, Yan T, Zhao H, Zhou JG, et al. Evaluation of eight different clinical staging systems associated with overall survival of chinese patients with hepatocellular carcinoma. Chin Med J (Engl). 2015;128:316\u201321.","journal-title":"Chin Med J (Engl)"},{"key":"720_CR19","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.jvir.2014.01.010","volume":"25","author":"K Memon","year":"2014","unstructured":"Memon K, Kulik LM, Lewandowski RJ, Wang E, et al. Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. J Vasc Interv Radiol. 2014;25:1056\u201366.","journal-title":"J Vasc Interv Radiol"},{"key":"720_CR20","first-page":"1375","volume":"57","author":"BI Carr","year":"2010","unstructured":"Carr BI, Irish W, Federle MP. Chemoembolization for unresectable hepatocellular carcinoma in patients with or without portal vein thrombosis. Hepatogastroenterology. 2010;57:1375\u201381.","journal-title":"Hepatogastroenterology"},{"key":"720_CR21","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1038\/s41598-020-60871-0","volume":"10","author":"N Kishi","year":"2020","unstructured":"Kishi N, Kanayama N, Hirata T, et al. Preoperative stereotactic body radiotherapy to portal vein tumour thrombus in hepatocellular carcinoma: clinical and pathological analysis. Sci Rep. 2020;10:4105. https:\/\/doi.org\/10.1038\/s41598-020-60871-0.","journal-title":"Sci Rep"},{"key":"720_CR22","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.2967\/jnumed.117.199752","volume":"59","author":"N Abouchaleh","year":"2018","unstructured":"Abouchaleh N, Gabr A, Ali R, et al. 90 Y Radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort. J Nucl Med. 2018;59:1042\u20138.","journal-title":"J Nucl Med"},{"issue":"10","key":"720_CR23","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.3390\/cancers12103025","volume":"12","author":"P Federico","year":"2020","unstructured":"Federico P, Petrillo A, Giordano P, et al. Immune checkpoint inhibitors in hepatocellular carcinoma: current status and novel perspectives. Cancers (Basel). 2020;12(10):3025. https:\/\/doi.org\/10.3390\/cancers12103025\u00a0(PMID: 33080958).","journal-title":"Cancers (Basel)"},{"key":"720_CR24","doi-asserted-by":"publisher","unstructured":"Kalasekar SM, Garrido-Laguna I, Evason KJ. Immune checkpoint inhibitors in novel combinations for hepatocellular carcinoma hepatology. 2021 Jan 12. doi: https:\/\/doi.org\/10.1002\/hep.31706. Online ahead of print. (PMID:\u00a033434363)","DOI":"10.1002\/hep.31706"},{"key":"720_CR25","doi-asserted-by":"publisher","unstructured":"Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review. JAMA Oncol. 2021 Jan 1;7(1):113\u2013123. doi: https:\/\/doi.org\/10.1001\/jamaoncol.2020.3381. (PMID: 33090190).","DOI":"10.1001\/jamaoncol.2020.3381"},{"key":"720_CR26","doi-asserted-by":"publisher","unstructured":"Wong JSL, Kwok GGW, Tang V et al. Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. Immunother Cancer. 2021 Feb;9(2):e001945.\u00a0https:\/\/doi.org\/10.1136\/jitc-2020-001945.","DOI":"10.1136\/jitc-2020-001945"},{"key":"720_CR27","doi-asserted-by":"publisher","unstructured":"Casak SJ, Donoghue M, Fashoyin-Aje L, et al. FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma. Clin Cancer Res. 2020 Nov 2.\u00a0https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3407. Online ahead of print. (PMID:\u00a033139264).","DOI":"10.1158\/1078-0432.CCR-20-3407"},{"key":"720_CR28","doi-asserted-by":"publisher","unstructured":"Refolo MG, Messa C, Guerra V, Carr BI, D'Alessandro R. Inflammatory mechanisms of HCC development \u00a0Cancers (Basel).\u00a02020;12:3\u2013641.\u00a0https:\/\/doi.org\/10.3390\/cancers12030641. (PMID: 32164265)","DOI":"10.3390\/cancers12030641"},{"key":"720_CR29","doi-asserted-by":"publisher","unstructured":"Leslie M. Cell biology. Beyond clotting: the powers of platelets. Science. 2010;328:562\u2013564.\u00a0https:\/\/doi.org\/10.1126\/science.328.5978.562.","DOI":"10.1126\/science.328.5978.562"},{"key":"720_CR30","doi-asserted-by":"crossref","unstructured":"Chen W, Jiang J, Wang PP, et al. Identifying hepatocellular carcinoma driver genes by integrative pathway crosstalk and protein interaction network. DNA Cell Biol. 2019;38:1112\u20131124.","DOI":"10.1089\/dna.2019.4869"},{"key":"720_CR31","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","volume":"149","author":"J Zucman-Rossi","year":"2015","unstructured":"Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. The genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149:1226\u201339.","journal-title":"Gastroenterology"},{"key":"720_CR32","first-page":"871","volume":"8","author":"L Guo","year":"2001","unstructured":"Guo L, Kuroda N, Toi M, et al. Increased expression of platelet-derived endothelial cell growth factor in human hepatocellular carcinomas correlated with high Edmondson grades and portal vein tumor thrombosis. Oncol Rep. 2001;8:871\u20136.","journal-title":"Oncol Rep"},{"key":"720_CR33","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N","volume":"91","author":"Y Koike","year":"2001","unstructured":"Koike Y, Shiratori Y, Sato S, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001;91:561\u20139.","journal-title":"Cancer"},{"key":"720_CR34","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/jjco\/hyg096","volume":"33","author":"M Gotoh","year":"2003","unstructured":"Gotoh M, Nakatani T, Masuda T, et al. Prediction of invasive activities in hepatocellular carcinomas with special reference to alpha-fetoprotein and des-gamma-carboxyprothrombin. Jpn J Cl Oncol. 2003;33:522\u20136.","journal-title":"Jpn J Cl Oncol"},{"key":"720_CR35","doi-asserted-by":"publisher","unstructured":"Yamazaki S, Takayama T, Kurokawa T, et al.\u00a0Next-generation des-r-carboxyprothrombin for immunohistochemical assessment of vascular invasion by hepatocellular carcinoma BMC Surg 2020;20:1\u2013201.\u00a0https:\/\/doi.org\/10.1186\/s12893-020-008620. (PMID:32928172 PMCID:PMC: 7491115).","DOI":"10.1186\/s12893-020-008620"},{"key":"720_CR36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/MEG.0000000000001526","volume":"32","author":"X Huang","year":"2020","unstructured":"Huang X, Fan X, Zhang R, Jiang S, Yang K, Chen S. Systemic inflammation and portal vein thrombosis in cirrhotic patients with gastroesophageal varices. Eur J Gastroenterol Hepatol. 2020;32:401\u20135.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"11","key":"720_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1477-7819-11-92","volume":"23","author":"JM Kim","year":"2013","unstructured":"Kim JM, Kwon CH, Joh JW, et al. World J Surg Oncol. 2013;23(11):92. https:\/\/doi.org\/10.1186\/1477-7819-11-92. (PMID: 23618082).","journal-title":"World J Surg Oncol"},{"key":"720_CR38","first-page":"1000428","volume":"10","author":"BI Carr","year":"2020","unstructured":"Carr BI, Akkiz H, Guerra V, et al. Erythrocyte sedimentation rate and C-reactive protein are markers for tumor aggressiveness and survival in patients with hepatocellular carcinoma. J Clinical Trials. 2020;10:1000428.","journal-title":"J Clinical Trials"},{"key":"720_CR39","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s12029-020-00489-7","volume":"51","author":"BI Carr","year":"2020","unstructured":"Carr BI, Guerra V, Donghia R. portal vein thrombosis and markers of inflammation in hepatocellular carcinoma. J Gastrointest Cancer. 2020;51:1141\u20137.","journal-title":"J Gastrointest Cancer"},{"key":"720_CR40","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1111\/j.1440-1746.2011.06796.x","volume":"26","author":"X Xu","year":"2011","unstructured":"Xu X, Wei X, Ling Q, et al. Identification of two portal vein tumor thrombosis associated proteins in hepatocellular carcinoma: protein disulfide-isomerase A6 and apolipoprotein A-I. J Gastroenterol Hepatol. 2011;26:1787\u201394.","journal-title":"J Gastroenterol Hepatol"},{"key":"720_CR41","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s00268-012-1866-8","volume":"37","author":"L Zhou","year":"2013","unstructured":"Zhou L, Jin Y, Cui QC, Jin KM, Zhou WX, Xing BC. Low expression of PAI-2 as a novel marker of portal vein tumor thrombosis and poor prognosis inhepatocellular carcinoma. World J Surg. 2013;37:608\u201313.","journal-title":"World J Surg"},{"issue":"Suppl 1","key":"720_CR42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000345895","volume":"84","author":"N Nishida","year":"2013","unstructured":"Nishida N, Arizumi T, Takita M, et al. Quantification of tumor DNA in serum and vascular invasion of human hepatocellular carcinoma. Oncology. 2013;84(Suppl 1):82\u20137. https:\/\/doi.org\/10.1159\/000345895.","journal-title":"Oncology"},{"key":"720_CR43","doi-asserted-by":"publisher","unstructured":"Carr BI, Guerra V, Donghia R et al. Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. Int J Biol Markers. 2021 Feb 27:1724600821996372.\u00a0https:\/\/doi.org\/10.1177\/1724600821996372. (Epub ahead of print. PMID: 33641486).","DOI":"10.1177\/1724600821996372"},{"key":"720_CR44","doi-asserted-by":"publisher","unstructured":"Liao W, Liu W, Liu X et al. Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma. Oncotarget.\u00a02015;6:24132\u201347. https:\/\/doi.org\/10.18632\/oncotarget.4432. (PMID:\u00a026125229 PMCID:\u00a0PMC4695175).","DOI":"10.18632\/oncotarget.4432"},{"key":"720_CR45","doi-asserted-by":"crossref","unstructured":"Huang T, Guo YZ, Yue X et al. Cripto-1 promotes tumor invasion and predicts poor outcomes in hepatocellular carcinoma. Carcinogenesis. 2020;4:571\u2013581.","DOI":"10.1093\/carcin\/bgz133"},{"key":"720_CR46","first-page":"1329","volume":"20","author":"J Akiba","year":"2008","unstructured":"Akiba J, Ogasawara S, Kawahara A, et al. N-myc downstream regulated gene 1 (NDRG1)\/Cap43 enhances portal vein invasion and intrahepatic metastasis in human hepatocellular carcinoma. Oncol Rep. 2008;20:1329\u201335.","journal-title":"Oncol Rep"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-021-00720-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-021-00720-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-021-00720-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T01:14:04Z","timestamp":1643332444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-021-00720-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["720"],"URL":"https:\/\/doi.org\/10.1007\/s12029-021-00720-z","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"type":"print","value":"1941-6628"},{"type":"electronic","value":"1941-6636"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"assertion":[{"value":"25 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work complies with the guidelines of the World Medical Association, Declaration of Helsinki. This work was approved by each institution\u2019s IRB as documented in the methods section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of Ethics"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}